IS8102A - Samsetning ras-farnesýltransferasatálma, sýklódextríns og etanóls - Google Patents

Samsetning ras-farnesýltransferasatálma, sýklódextríns og etanóls

Info

Publication number
IS8102A
IS8102A IS8102A IS8102A IS8102A IS 8102 A IS8102 A IS 8102A IS 8102 A IS8102 A IS 8102A IS 8102 A IS8102 A IS 8102A IS 8102 A IS8102 A IS 8102A
Authority
IS
Iceland
Prior art keywords
ras
cyclodextrin
ethanol
composition
farnesyltransferase inhibitors
Prior art date
Application number
IS8102A
Other languages
English (en)
Icelandic (is)
Inventor
Marie Smith Anne
Cucolo Michael
N. Nassar Munir
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS8102A publication Critical patent/IS8102A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS8102A 2003-05-02 2005-10-28 Samsetning ras-farnesýltransferasatálma, sýklódextríns og etanóls IS8102A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46728703P 2003-05-02 2003-05-02
PCT/US2004/013114 WO2004098501A2 (en) 2003-05-02 2004-04-27 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol

Publications (1)

Publication Number Publication Date
IS8102A true IS8102A (is) 2005-10-28

Family

ID=33435047

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8102A IS8102A (is) 2003-05-02 2005-10-28 Samsetning ras-farnesýltransferasatálma, sýklódextríns og etanóls

Country Status (6)

Country Link
US (1) US7157446B2 (enExample)
EP (1) EP1622628A4 (enExample)
JP (2) JP2006525341A (enExample)
IS (1) IS8102A (enExample)
NO (1) NO20055128L (enExample)
WO (1) WO2004098501A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
HU199444B (en) * 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
YU45837B (sh) * 1988-01-18 1992-07-20 LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1251615B (it) * 1991-10-04 1995-05-17 Golgi Sa Medicamento ad attivita' antielastasica.
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US5646131A (en) 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
CZ20012601A3 (cs) * 1999-01-21 2002-05-15 Bristol-Myers Squibb Company Komplex inhibitoru ras-farnesyltranferasy a sulfobutylether-7beta-cyklodextrinu nebo 2-hydroxypropyl-beta-cyklodextrinu a způsob

Also Published As

Publication number Publication date
EP1622628A4 (en) 2010-03-03
WO2004098501A3 (en) 2005-03-17
US7157446B2 (en) 2007-01-02
NO20055128D0 (no) 2005-11-02
JP2012072161A (ja) 2012-04-12
US20040235790A1 (en) 2004-11-25
EP1622628A2 (en) 2006-02-08
WO2004098501A2 (en) 2004-11-18
NO20055128L (no) 2005-12-01
JP2006525341A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
NL350092I2 (nl) Combinatie van bixafen en fluoxastrobine
DK2302055T3 (da) Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
DK1648426T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
PT1586571E (pt) Inibidores da dipeptidil-peptidase
NO2017017I1 (no) umeklinidium og vilanterol
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1756064T3 (da) Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
NO20055018D0 (no) Anti-amyolide antistoffer, sammensetninger, fremgangsmater og anvendelser
DK1913001T3 (da) (r)-n-methylnaltrexon, fremgangsmåder til syntese og farmaceutisk anvendelse heraf
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20054453L (no) P38 inhibitorer og fremgangsmater for anvendelse derav
DK1751087T3 (da) Levodopa-derivater og sammensætninger og anvendelser deraf
DK1606283T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
DE602004018837D1 (de) Ptidase-iv-inhibitoren
IS8146A (is) Setnar 3-alkýl og 3-alkenýl asetidín afleiður
DK1771421T3 (da) N-hydroxyamidderivater og anvendelse deraf
DK3309233T3 (da) Sammensætninger omfattende hfc-1234yf og hfc-152a
DK1732892T3 (da) Tetrahydrocarbazoler og derivater
DK1685150T3 (da) Hidtil ukendte 17beta-hydroxysteroiddehydrogenase type I-inhibitorer
DK1611115T3 (da) Benzothiazolderivatforbindelser, sammensætninger og anvendelser deraf